PPARs and mitochondrial metabolism: From NAFLD to HCC by Mello, T. et al.
Review Article
PPARs and Mitochondrial Metabolism: From NAFLD to HCC
TommasoMello,1 Maria Materozzi,1 and Andrea Galli1,2
1Clinical Gastroenterology Unit, Department of Biomedical Clinical and Experimental Sciences “Mario Serio”,
University of Florence, Viale Pieraccini 6, 50129 Florence, Italy
2Careggi University Hospital, Florence, Italy
Correspondence should be addressed to Tommaso Mello; tommaso.mello@unifi.it
Received 22 July 2016; Revised 8 November 2016; Accepted 10 November 2016
Academic Editor: Daniele Fanale
Copyright © 2016 Tommaso Mello et al.This is an open access article distributed under theCreativeCommonsAttribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Metabolic related diseases, such as type 2 diabetes, metabolic syndrome, and nonalcoholic fatty liver disease (NAFLD), are
widespread threats which bring about a significant burden of deaths worldwide,mainly due to cardiovascular events and cancer.The
pathogenesis of these diseases is extremely complex, multifactorial, and only partially understood. As themainmetabolic organ, the
liver is central to maintain whole body energetic homeostasis. At the cellular level, mitochondria are the metabolic hub connecting
and integrating all the main biochemical, hormonal, and inflammatory signaling pathways to fulfill the energetic and biosynthetic
demand of the cell. In the liver,mitochondriametabolismneeds to copewith the energetic regulation of the whole body.The nuclear
receptors PPARs orchestrate lipid and glucose metabolism and are involved in a variety of diseases, from metabolic disorders to
cancer. In this review, focus is placed on the roles of PPARs in the regulation of liver mitochondrial metabolism in physiology and
pathology, from NAFLD to HCC.
1. Introduction
Liver cancer is a major challenge in contemporary medicine.
It represents the fifth most common cancer in men, the
ninth in women, and the second most frequent cause of
mortality among oncological patients. It was responsible for
nearly 746,000 deaths in 2012, with an estimated incidence of
over 780,000 new cases yearly worldwide [1]. The prognosis
for liver cancer is extremely poor (overall ratio of mortality
to incidence of 0.95), reflecting the absence of effective
treatments. The most frequent type of primary liver cancer is
hepatocellular carcinoma (HCC), accounting for up to 85%
of total cancers [2].
Major risk factors include HBV or HCV infection, alco-
holic liver disease, and most likely nonalcoholic liver disease
(NAFLD) [2]. These and other chronic liver diseases lead to
cirrhosis, which is found in 80–90% of HCC patients [2].
NAFLD is now the most common liver disease worldwide
[3], with a global prevalence of about 25%. NAFLD is closely
associated with other metabolic disorders such as obesity,
metabolic syndrome, and type 2 diabetes [3]. Indeed, obesity
and diabetes are now definitively recognized as independent
risk factors for the development of HCC [4, 5]. NAFLD is
histologically classified into nonalcoholic fatty liver (NALF),
defined as the presence of steatosis in the absence of
causes for secondary hepatic fat accumulation (i.e., alcohol
consumption, steatogenic drugs, or genetic disorders), and
nonalcoholic steatohepatitis (NASH), in which steatosis is
complicated by inflammation and hepatocellular damage
(ballooning hepatocytes), with or without fibrosis [6]. A
relatively small portion ofNAFL patients evolve intoNASH, a
progressive type of liver disease with the potential of evolving
into cirrhosis and HCC.The cumulative incidence of HCC in
NASH cirrhosis ranges from 2.4% to 12.8%, and although it
is lower than in HCV cirrhotic patients, the absolute burden
of NASH related HCC is higher due to the epidemic spread
of NAFLD [7]. Moreover, NAFLD greatly increases the risk
of HCC from other aetiologies, especially HCV and HBV.
While the vast majority of HCC arise in cirrhotic livers,
it can also occur in noncirrhotic patients [2]. Of notice, a
significant amount of newHCC cases is diagnosed in patients
with noncirrhotic NASH [4, 8]. The global incidence of HCC
among NAFLD patients was recently estimated to be 0.44
per 1,000 person-year [3], which combinedwith the epidemic
spread of metabolic disorders results in an enormous burden.
The recentmeta-analysis byYounossi et al. raised the question
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whether NAFLD could even precede the onset of metabolic
syndrome rather than just being the hepatic manifestation of
it [3].
The mechanisms that promote HCC development in
NASH/NAFLD patients are complex and still poorly under-
stood. A number of molecular mechanisms have been linked
to obesity and relatedmetabolic disorders thatmay accelerate
the development of HCC, such as adipose-derived inflam-
mation, lipotoxicity, and insulin resistance. These and other
pathological events in obesity have complex interactions
while their relative contribution to hepatocarcinogenesis in
various stages of NAFLD progression remains to be deter-
mined.
Mitochondria can be seen as the energetic hub of the
cell. As such, beyond their role in energy production, they
play a central role in coordinating the cell anabolic and
catabolic processes, in balancing the cell energetic demands
in response to internal and external stimuli, and in the
regulation of several cell signaling pathways. Deregulation of
mitochondrial activity is a common trait to several human
diseases, including cancer. Since Warburg, it has long been
known that cancer cells undergo a radical metabolic shift
toward glycolysis, irrespective of the oxygen availability
(aerobic glycolysis) [9]. However, the actual significance of
this metabolic remodeling, its consequences on cancer cell
biology, and its plasticity have begun to be grasped only in
recent years. The initial perception of the Warburg effects
was that cancer cells rely primarily on glycolysis for energy
production due to a defective mitochondrial respiration [10].
On the contrary, it is now clear that cancer cells hijack
theirmitochondriametabolism towardmassive anabolic pro-
cesses, in order to cope with the cell fast-growing rates [11]. In
this line of view, exacerbate biosynthesis, in particular lipid
biosynthesis, rather than glycolysis dependence, emerges as
cancer metabolic hallmark.
Peroxisome proliferator activated receptors (PPARs) are
master regulators of whole body and liver metabolism.
Despite a similar structure, the three PPAR isotypes 𝛼, 𝛽/𝛿,
and 𝛾 vary greatly in tissue distribution, pharmacological
and endogenous ligands, and biological effects. In the past
decades PPARs have been the focus of massive research
effort that helped uncovering their contribution to can-
cer, metabolic, and cardiovascular diseases. The different
PPAR isotypes regulate lipid metabolism by a number of
mechanisms: (i) controlling the rate of FA disposal through
mitochondrial and peroxysomal 𝛽-oxidation (FAO), (ii)
regulating lipid biosynthesis via de novo lipogenesis, (iii)
regulating FA uptake in peripheral tissue and in the liver, (iv)
regulating whole body lipid trafficking through apolipopro-
teins, (v) interacting in complex regulatory network with
other nuclear receptors (LXR, FXR), coactivators (PGC-1𝛼
and 𝛽, SREBP), or corepressors (NCOR) involved in the
metabolic homeostasis. As liver is primarily a metabolic
organ, PPARs-regulated processes are involved virtually in
any liver disease.
This review summarizes current notions on the roles of
PPARs in the regulation of liver mitochondrial metabolism
in physiology and pathology, from NAFLD to HCC.
2. PPARs and Mitochondrial Metabolism
in the Liver
2.1. PPAR𝛼. Peroxisome proliferator activated receptor 𝛼
(PPAR𝛼) is the main PPAR isotype expressed in the liver
and plays a major role in energy homeostasis, by regulating
lipid metabolism and ketone body formation [12]. In mice
but not in humans, PPAR𝛼 also controls the glycolysis-
gluconeogenesis pathway [13]. PPAR𝛼 natural ligands are
endogenous lipids such as fatty acids (FA) and their deriva-
tives (eicosanoids, oxidized phospholipids) [14], while syn-
thetic ligands include the class of hypolipidemic drugs
fibrates, xenobiotic agents, and plasticizers.
Despite the fact that FA and derivatives can bind and
activate PPAR𝛼 in the liver, not all FA are created equal.
Indeed, it has been now recognized that FA released in the
bloodstream by the adipose tissue (i.e., during fasting or
intense physical exercise) have little role as PPAR𝛼 agonist
[15], while preferentially activating PPAR𝛽/𝛿, whereas fatty
acids derived from dietary intake or de novo lipogenesis
are efficient PPAR𝛼 activators [15–18]. However, PPAR𝛼 is
absolutely required for the metabolic adaptation to fasting,
since PPAR𝛼−/− mice, either full body [19] or liver-specific
[20], develop steatosis with prolonged fasting. Moreover,
the time course activation of PPAR𝛼 in the liver mimics
the kinetics of circulating FFA during fasting, and liver
transcriptomic profiling revealed that the fasted state (ver-
sus fed or refed) triggered the broader PPAR𝛼-dependent
response, strengthening the functional link between hepatic
PPAR𝛼 and adipose tissue-FA disposal [20]. Since activation
of hepatic PPAR𝛼 requires de novo lipogenesis [15, 21], the
mechanisms that fine-tune PPAR𝛼 activation in different
metabolic conditions are still unclear and possibly involve
separate pools of PPAR𝛼 that can be activated in a context-
dependent manner.
Moreover, the adipose tissue cross-talk with the hepatic
PPARs can occur via adiponectin-induced FAO, which is
dependent upon AdipoR2 subtype and requires PPAR𝛼
induction [22], and via FGF21, produced mainly in the liver
in a PPAR𝛼-dependent manner [20], which promotes both
glucose uptake and lipolysis in the adipocytes [23], as well as
hepatic lipid disposal [24].
In hepatocytes, PPAR𝛼 promotes the expression of sev-
eral genes involved in FA uptake, activation to acyl-CoA,
and transport to the mitochondria or peroxisomes and
subsequent 𝛽- or 𝜔-oxidation, ketogenesis, and lipoprotein
trafficking [25, 26] (Figure 1).
Many of the PPAR𝛼 regulated genes directly modulate
mitochondrial metabolism. Interestingly, among the many
PPAR𝛼-regulated genes in hepatocytes, those involved in
mitochondrial metabolic functions, especially in fatty acid
oxidation, are consistently dependent upon PPAR𝛼 regard-
less of the nutritional condition [20]. PPAR𝛼 target genes
are also carnitine palmitoyl transferase 1 (CPT-1) and carni-
tine palmitoyltransferase 2 (CPT-2) [19, 25], which mediate
transport of long-chain fatty acids through the outer and
inner mitochondrial membrane, respectively, to initiate their
degradation in the 𝛽-oxidative pathway (Figure 1). The
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Figure 1: Role of hepatic PPARs in mitochondrial metabolism: fatty acid oxidation, circadian control of NAD+ dependent SIRT activity, de
novo lipogenesis, and gluconeogenesis. Color-coding depicts PPAR isotypes-dependency of target genes.
𝛽-oxidation cycle consists of four reactions, catalyzed by
acyl-CoA dehydrogenases (ACADs), enoyl-CoA hydratases,
L-3-hydroxyacyl-CoA dehydrogenase, and 3-ketoacyl-CoA
thiolase, that sequentially remove two carbons—one acetyl-
CoA molecule, until the acyl-CoA is completely converted
to acetyl-CoA. The initial step of the 𝛽-oxidation cycle is
catalyzed by length specific acyl-CoA dehydrogenases (such
as ACADM,ACADS, andACADVL), all of which are PPAR𝛼
target genes [26]. The last three steps are carried on by the
mitochondrial trifunctional protein (MTP), a large complex
of four 𝛼 and four𝛽 subunits.The expression of both subunits
(encoded by genes HADHA, HADHB) as well as the MTP
protein 3-ketoacyl-CoA thiolase (encoded by ACAA2) is
regulated by PPAR𝛼 [26].
The acetyl-CoA produced during FAO is then used to
produce ketone bodies (acetoacetate and 𝛽-hydroxybutyrate)
via mitochondrial HMG-CoA synthase, another PPAR𝛼
regulated gene [27]. Ketone bodies are released in the blood
stream and, after conversion to citrate, fuel the TCA cycle in
peripheral tissues (mostly heart, muscle, and brain).
FAO is functionally and physically linked to OXPHOS:
the reducing equivalents produced by FAO are directly
used by the electron transport chain (ETC); moreover, the
two pathways are likely happening in large mitochondrial
supercomplexes containing both FAO and ETC complexes
[28]. Therefore, an unbalance in FAO or ETC directly affects
the other pathway.
PPAR𝛼, as well as 𝛽/𝛿 and 𝛾, also induces the expression
of all uncoupling protein (UCP-1, UCP-2, and UCP-3), of
which UCP-2 is the main type expressed in liver [29, 30].
Uncoupling proteins allow protons to reenter the mitochon-
drial matrix without production of adenosine triphosphate,
thus promoting energy expenditure and FA oxidation.
Paralleling its role in promoting energy expenditure
through FA disposal, PPAR𝛼 also inhibits the lipogenic
pathway by induction of the malonyl-CoA decarboxylase
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which degradesmalonyl-CoA, a precursor of FA biosynthesis
and inhibitor of the mitochondrial transporter CPT-1 [31]
(Figure 1).
2.2. PPAR𝛽/𝛿. PPAR𝛽/𝛿 is ubiquitously expressed, often at
higher level than PPAR𝛼 or 𝛾. Overall, PPAR𝛽/𝛿 role in lipid
metabolism appears to be largely overlapping with PPAR𝛼
in most tissues. Indeed, PPAR𝛽/𝛿 stimulates FAO in muscle
and heart, the latter organ being extremely dependent on
PPAR𝛽/𝛿 function [32].
Several PPAR𝛼 target genes are thus not surprisingly
induced also by PPPAR𝛽/𝛿 (UCP-1, UCP-2, and UCP-3,
FABP, FAT/CD36, LPL, ACS, and CPT-1) [33, 34] and loss
of PPAR𝛼 in muscle is efficiently compensated by PPAR𝛽/𝛿
[33]. Indeed, numerous studies have shown that PPAR𝛽/𝛿
overexpression or activation inmuscle dramatically improves
FA utilization as energy source, reduces hyperlipidemia,
improves endurance, and decreases insulin secretion from 𝛽-
cells [32, 35–37].
However, in the liver PPAR𝛽/𝛿 seems to play a different
role than PPAR𝛼. Adenoviral-mediated overexpression of
PPAR𝛽/𝛿 in the liver enhanced glucose utilization either to
increase glycogen storage or to promote de novo lipogen-
esis, rather than inducing FAO [38] (Figure 1). PPAR𝛽/𝛿
induced the expression of several genes involved in glu-
cose metabolism (GLUT2, GK, and pyruvate kinase) and
lipogenesis (FAS, ACC1, ACC2, SCD1, SREBP-1c, and PGC-
1𝛽) [38]. Conversely, gluconeogenesis genes (PEPCK, HNF-
4) were inhibited by PPAR𝛽/𝛿 expression in hepatocytes.
Importantly, the levels of PPAR𝛼 and its target (CPT-1,
acyl-CoA oxidase, and MCAD) were unaffected; therefore
PPAR𝛽/𝛿 seems not to overlap with PPAR𝛼 function in the
liver [38]. Consistently, whole transcriptome profiling and
liver metabolites analysis of PPAR𝛼−/− and PPAR𝛽/𝛿−/−mice
revealed clearly divergent roles [39]. Very interestingly, liver
PPAR𝛽/𝛿 signals to PPAR𝛼 and activates FAO in muscle via
the lipid molecule PC (18:0/18:1), whose production in the
liver is PPAR𝛽/𝛿-dependent [40].
Different roles for PPAR𝛼 and PPAR𝛽/𝛿 in mitochondri-
ogenesis are also beginning to emerge. A transitory upregula-
tion of PPAR𝛼, and consequent induction of PGC-1𝛼, is nec-
essary to promote mitochondriogenesis in the early steps of
differentiating embryonic stem cells. A robust upregulation of
PPAR𝛽/𝛿 is instead needed to promote mitochondriogenesis
at later stages of cells differentiation and correlates with the
expression of mature hepatocytic markers [41].
Functional peroxisome proliferator response elements
have been identified in the distal promoter of PGC-1𝛼, pro-
viding the mechanistic basis for PPAR-induced mitochon-
drial biogenesis. However, the contribution of the diverse
PPAR isotypes to PGC-1𝛼 induction appears to be cell
context-dependent. PGC-1𝛼 is activated by PPAR𝛼 in brown
adipose tissue [42] and by PPAR𝛾 in both white and brown
adipose tissue [42]. In skeletal muscle, PPAR𝛽/𝛿 but not
PPAR𝛼 induce PGC-1𝛼 expression [43, 44].
In liver, PCG-1𝛼 is induced by fasting, paralleling PPAR𝛼
activation, and promotes gluconeogenesis, a process medi-
ated by PPAR𝛽/𝛿 [45].
2.3. PPAR𝛾. PPAR𝛾 is the main PPAR isotype expressed in
white and brown adipose tissue. It is the master inducer of
adipogenesis and promotes glucose uptake and utilization
in the novo lipogenic pathway, therefore regulating whole
body lipidmetabolism and insulin sensitivity. Natural PPAR𝛾
ligands are lipid molecules derivates, such as unsaturated FA,
PGJ2, and oxidized LDL [14, 46, 47] while potent synthetic
ligands include the insulin sensitizer class of drug TZD [48].
PPAR𝛾 induces the expression of genes regulating glucose
sensitivity (GLUT-4, IRS-1, IRS-2, and PI3K), as well as
genes involved in FA uptake and mobilization (FAT/CD36,
fatty acids binding proteins aP2, and lipoprotein lipase)
and triglyceride synthesis (acyl-CoA synthetase, glycerol
kinase, and PEPCK) [46, 49] (Figure 1). In the liver, PPAR𝛾
is expressed in macrophages, endothelial cells, quiescent
(nonactivated) stellate cells, and hepatocytes. Its complex
actions on liver physiology are mostly mediated by its
anti-inflammatory functions on macrophages and endothe-
lial cells, antifibrotic function in hepatic stellate cells, and
metabolic cross-talk between hepatocytes and adipocytes via
FGF family members (FGF21, FGF-1). Mice with selective
deletion of PPAR𝛾 in hepatocytes developed relative fat
intolerance, increased adiposity, hyperlipidemia, and insulin
resistance. Loss of hepatic PPAR𝛾 increased TG blood
level and redistribution to other tissues, aggravating insulin
resistance in muscle and adipose tissue [50, 51]. These
models highlighted the role of liver PPAR𝛾 in maintaining
lipid/glucose homeostasis and insulin sensitivity.
PPAR𝛾 also induces the expression of mitochondrial pro-
teins, common to the other PPARs, such as CPT-1 and UCPs,
suggesting a possible degree of overlap in mitochondrial
metabolism regulation with other PPAR members. Probably
themost relevant function of PPAR𝛾 inmitochondria biology
comeswith its interactionwith PGC-1 familymembers. PGC-
1𝛼 was initially identified as a nuclear PPAR𝛾 coactivator in
mitochondrial rich brown adipose tissue-tissue [52]. Since
then, it has become clear that PGC-1𝛼 and 𝛽 control virtually
any aspect of mitochondria function and biogenesis [53],
by thoroughly coordinating a plethora of nuclear receptors
(including all three PPARs, EER𝛼) and nonnuclear receptor
protein [54]. Indeed, PPAR𝛾 can promote the expression
of PGC-1𝛼, which in turn potentiates PPAR𝛾 activity [55].
Recently, steatogenic FA were shown to induce PPAR𝛾 via
PGC-1𝛼, suggesting a link between mitochondria biogenesis
and triglyceride accumulation [56].
3. Mechanisms of Mitochondrial Oxidative
Stress Damage
Reactive oxygen species (ROS) are small reactive molecules
generated by the normal cell metabolism, involved in homeo-
stasis and signaling. ROS such as superoxide anion (O2
−),
hydrogen peroxide (H2O2), and hydroxyl radical (HO
∙)
consist of radical and nonradical oxygen species formed
by the partial reduction of oxygen. Cellular ROS levels are
controlled by antioxidant systems such as reduced/oxidized
glutathione (GSH/GSSG), reduced/oxidized cysteine
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(Cys/CySS), tioredoxin (Trx), peroxiredoxin (Prx), super-
oxide dismutase (SOD), and catalase.
An imbalance of the generation/neutralization of ROS,
driven by an overproduction of ROS or a depletion of the
antioxidant defenses, leads to a prooxidant state defined as
“oxidative stress.” Oxidative stress can directly damage pro-
teins, lipids, and DNA, leading to damaged macromolecules
and organelles, but also deranges the redox circuits that
regulate many signaling pathways [57]. In fact, while exces-
sively high levels of oxidative stress lead the cell to apoptosis,
a controlled increase of ROS serves as critical signaling
molecules in cell proliferation and survival [58]. ROS can be
generated by growth factor signaling through activation of
the NADPH oxidase NOX1 or through the mitochondria. In
turn, they can induce cellular signaling cascades by oxidation
of phosphatases such as PTEN or PTP or kinases such as
Src. This leads to the activation of several pathways such as
a Src/PKD1-dependent NF-𝜅B activationmechanism,MAPK
(Erk1/2, p38, and JNK), and the PI3K/Akt signaling. Aberrant
levels of ROS induce a deregulation of these pathways,
which are involved in several pathological conditions, such
as NAFLD [59], diabetes [60], and cancer [58, 61].
Several different sources of ROS exist in mitochondria.
ETC complex I and complex II, as well as othermitochondrial
enzymes such as 𝛼-ketoglutarate dehydrogenase, pyruvate
phosphate dehydrogenase, fatty acyl-CoA dehydrogenase,
and glycerol 3-phosphate dehydrogenase, can produce O2
∙−
as byproduct, releasing it within the mitochondrial matrix.
Moreover, H2O2 is produced by the monoamine oxidases
(MAOs) located in the outer mitochondrial membrane
[62, 63]. Therefore, mitochondria can produce a significant
amount of ROS during OXPHOS and FAO, especially in the
context of reduced antioxidant defense such as depletion of
the mitochondrial glutathione pool [64].
Four main alterations are the direct result of ROS for-
mation: lipid, protein and DNA oxidation, and depletion of
antioxidant molecules.
Mitochondrial DNA (mtDNA) is particularly suscep-
tible to oxidative damage due to the absence of protec-
tive histones, incomplete DNA repair mechanisms, and the
close proximity to ROS production site, which increase the
risk of double-strand breaks and somatic mutations with
increased ROS production [65]. Since the ETC proteins are
encoded exclusively in mtDNA, oxidative damage leads to
defective mitochondrial respiration and to a second burst
of ROS production that damages mitochondrial membrane
and eventually results in loss of mitochondrial membrane
potential and activation of proapoptotic pathways due to
the ROS induced-ROS-release avalanche [64, 65]. Indeed,
depletion and mutation of mtDNA have been described in
several type of liver injury, including NASH [66].
Lipid peroxidation is the process under which lipids,
mainly polyunsaturated fatty acids, are attacked by oxidants
such as ROS. These reactions can form a variety of pri-
mary and secondary products, among which malondialde-
hyde (MDA) appears to be the most mutagenic and 4-
hydroxynonenal (4-HNE) the most toxic. MDA induced
mutations are involved in cancer and other genetic diseases.
4-HNE can also act as a signalingmoleculemodulatingmany
pathways and inducing the expression of proteins, such as
NF-𝜅B, Akt, MAPK, JNK, and PPARs. Lipid peroxidation
occurs through a radical reaction; it is therefore extremely
harmful to biological membranes where the damage can
rapidly spread.
The depletion of mitochondrial ROS scavenger is a key
step in the pathogenesis of ROS-related liver disease.
In NASH animal model, depletion of mGSH occurs due
to cholesterol accumulation in the mitochondrial membrane
[67] that disrupts the functionality of GSH transport from
cytosol to mitochondria. Depletion of mGSH and other
antioxidant systems are documented in NASH patients [68].
ROS can also act as second messengers in cellular sig-
naling oxidizing proteins on cysteine residues, resulting in
protein activation or inhibition.High levels of ROS can there-
fore activate pathways in a signal-independent manner and
self-sustain many proproliferative pathways highly involved
in cancer and liver diseases such as NASH/NAFLD.
For example, it has been demonstrated that ROS can
directly oxidize and activate complexes such as inflam-
masomes: protein platforms that assemble in the pres-
ence of exogenous or endogenous danger signals such
as pathogen associated molecular patterns (PAMPs) and
damage-associated molecular patterns (DAMPs) to activate
and amplify inflammatory pathways [69]. Typically, inflam-
masomes consist of a sensor (NLRs, ALRs, and TLRs), an
adaptor (ASC), and the effector molecule caspase-1 [70].
Once caspase-1 is recruited and activated through autocat-
alytic cleavage by the inflammasome, it can proteolytically
process the inflammatory cytokines IL-1𝛽 and IL-18 that lead
to a specialized form of cell death called pyroptosis. Pyropto-
sis causes the release of IL-1𝛽 and amplify the inflammatory
response downstream of inflammasome activation [70]. In
the liver, inflammasomes are expressed in hepatocytes as
well as in immune cells and can also be activated by fatty
acids through a mechanism involving mitochondrial ROS,
decreased autophagy, and IL-1𝛽 secretion. Inflammasomes
are found overexpressed in NAFLD and NASH and their
silencing reduced hepatic injury, steatosis, and fibrosis [69].
Interestingly, agonists of PPAR𝛽/𝛿 were shown to reduce
fatty acid induced inflammation and steatosis by inhibiting
inflammasomes [69, 71].
Lipid overload in NAFLD and NASH leads to mitochon-
drial dysfunction and increased oxidative stress, which results
from both increased electron flux through the ETC and
depletion of the mitochondrial antioxidant defense systems
[64].
Reduced levels of GSH, SOD, and catalase as well as
increased protein oxidation, a hallmark of increased oxidative
stress, are found in NASH patients [68]. Consistently, the
mitochondria of NASH patients have altered morphology
[72, 73], reduced or mutated mDNA content [66], and
reduced oxidative phosphorylation capacity [74]. Oxidative
stress constitutes one of the key factors driving NAFLD
progression to NASH [75]. Indeed, histological markers of
oxidative stress, such as oxidized phosphatidylcholine, local-
ize into steatotic/apoptotic hepatocytes andmacrophages and
correlate with the degree of steatosis [76].
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are recapitulated also in several animal models of NASH.
Interestingly, Llacuna and colleagues highlighted that mito-
chondrial damage in diverse animalmodels of NASH seemed
to be dependent more on mitochondria cholesterol accumu-
lation (ob/ob mice or HFD administration), rather than only
fatty acid/triglyceride overload (choline deficiency model)
[67]. Consistently, statins reduced mitochondrial damage in
ob/ob mice and HFD models.
This line of view is confirmed by a recent report high-
lighting the crucial role of dietary cholesterol in delivering
the “second hit” for NASH onset, in context of moderate
dietary fat administration (45%of total calories from fat) [77].
In this study, addition of a moderate level of cholesterol in
HF elicits the onset of hepatocellular damage and inflam-
mation through activation of the inflammasomes response,
while neither dietary cholesterol nor HF alone produced
the NASH phenotype. Importantly, addition of cholesterol
to HF resulted in blunted adaptation of mitochondrial
metabolism to HF and markedly reduced mitochondrial
biogenesis, effects paralleled by a decrease in PGC-1𝛼 and
TFAMexpression levels [77].Moreover, while hepatic inflam-
mation recovered after removal of excess dietary cholesterol,
mitochondrial functions remained hampered alongside ele-
vated NRLP3 inflammasome protein levels, indicating slow
recovery dynamics from mitochondrial damage.
Excess accumulation of free cholesterol in mitochondrial
membranes emerges as a hallmark of cellular transformation,
potentially fueling the metabolic derangement required for
cancer cell growth and resistance to apoptosis [78].
4. PPARs and Mitochondrial Dysfunction,
from NAFLD to HCC
4.1. PPAR𝛼. A role for PPAR𝛼 in NASH pathogenesis in
animal models has long been established.
PPAR𝛼−/− mice fed a MCD diet developed more severe
NASH than WT mice, and Wy-14,643 administration com-
pletely prevented the development of NASH in WT mice,
but not in PPAR𝛼−/− mice [79]. The protective effect of the
PPAR𝛼 agonist Wy-14,643 was unexpected, since the authors
had foreseen a detrimental effect of the oxidative stress pro-
duced by peroxysomal 𝜔-oxidation after PPAR𝛼 activation.
However, PPAR𝛼 activation also resulted in increased hepatic
lipid turnover through the 𝛽-oxidative pathway, preventing
accumulation of lipoperoxides despite peroxysomal induc-
tion [79]. The beneficial effects of PPAR𝛼 activation by Wy-
14,643 were also confirmed in a severe NASH model with
established fibrosis [80].
PPAR𝛼 deletion in mice results in mild, age and sex-
dependent, lipid accumulation in the liver [81]. Moreover,
overnight fasting results in severe hypoglycemia, hypoke-
tonemia, and increased plasma free FA levels, impaired 𝛽-
oxidation, and ketogenesis in PPAR𝛼−/−mice [19]. As a result,
HFD feeding worsens NAFLD in PPAR𝛼−/− mice [19, 82].
More recently, the use of a hepatocytic specific PPAR𝛼−/−
mice model confirmed the protective role of PPAR𝛼 in
NAFLD induced by MCD and short-term HFD. Interest-
ingly, PPAR𝛼ℎ𝑒𝑝−/− mice developed steatosis and hyperc-
holesterolemia with aging similarly to whole body PPAR𝛼−/−
mice but did not become obese nor hyperglycaemic [20],
confirming that hepatocytic PPAR𝛼 deletion by itself is a
primary cause of liver steatosis.
On the other hand, in leptin deficient (ob/ob) and
leptin resistant (db/db) mouse models, PPAR𝛼 expression
was found reduced, unchanged, or increased [83]. Rate of
FAO also varies greatly depending on the study. While these
discrepancies could be generated by different study protocols,
they may be interpreted also in the light of different PPAR𝛼
pools that can be differentially activated in the metabolism of
dietary, versus adipose tissue-derived fatty acids.
Since FA can bind and activate PPAR𝛼, thus promoting
mitochondrial and peroxysomal FAO, downregulation of
PPAR𝛼 in NASH mice models and patients may be counter-
intuitive. Moreover, high FAO can increase oxidative stress;
therefore stimulating PPAR𝛼 activity and FAO is somewhat
expected to worsen the oxidative damage in hepatocytes.
However, it should be recalled that although mitochondria
are potentially a major source of ROS, they are also very well
equipped with antioxidant defense systems. In fact, whether
significant ROS production occurs in mitochondria in vivo is
highly debated, and the endoplasmic reticulum is currently
emerging as the major source or toxic ROS within the cell
[64].The current view is that liver triglycerides accumulation
per se does not result in inflammation [84, 85]. Rather, accu-
mulation of free fatty acids, in particular saturated fatty acids
(SFA), results in marked lipotoxicity, hepatocellular damage,
and inflammation [86, 87]. The onset of inflammation drives
the progression from NAFLD to NASH and causes PPAR𝛼
downregulation by TNF𝛼 [88]. Moreover, TNF𝛼 also reduces
adiponectin levels. Adiponectin promotes FAO and blunts
liver gluconeogenesis signaling through AdipoR2 receptor,
which promotes PPAR𝛼 activity [89] and depends upon
PPAR𝛼 induction. Thus, inflammation-mediated disruption
of themetabolic cross-talk between the adipose tissue and the
liver may account for reduced PPAR𝛼 activity, mitochondrial
dysfunction, and NASH development (Figure 2). A recent
report by Ande and coworkers highlights the importance of
the inflammatory cross-talk between adipose tissue and liver,
in a sex-dependent manner, in the induction of hepatocytes
mitochondrial dysfunction, NASH, and HCC development
[90].
This line of view is consistent with the emerging role of
PPAR𝛼 in the control of inflammation [12] and provides
additional rationale for pharmacological induction of PPAR𝛼
in NASH treatment.
Reports on PPAR𝛼 in human NAFLD are scarce. Very
recently a thorough investigation of PPARs expression in
NAFLDpatients was assessed by Staels’ group.The expression
of PPAR𝛼, PPAR𝛽/𝛿, and PPAR𝛾 was evaluated on mRNA
extracted from paired liver biopsies collected 1 year apart
in 85 patients. They found a significant association between
decreased PPAR𝛼 expression and histological severity of
NASH. No correlation was found with PPAR𝛽/𝛿 or PPAR𝛾
expression [91].
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The PPAR𝛼 agonists peroxisome proliferators exhibit
liver cancerogenic activity when chronically administered
in mice. The tumor promoting activity has been related
to massive proliferation of peroxisomes, with consequent
oxidative stress, and to inhibition of let-7c, a microRNA
that represses c-myc expression [92]. Long-term HCC devel-
opment was also found to be dependent with sustained
PPAR𝛼 activation in a transgenic model overexpressing the
HCV core protein [93]. However, humans are resistant to
peroxisome proliferation and indeed no association between
fibrates and increased risk of any cancer has ever been found
[94, 95].
Recently, PPAR𝛼−/− mice were found to be more suscep-
tible to DEN-induced HCC, and PPAR𝛼 anticancer activity
was shown to be mediated by NF-kB inhibition [96].
Interestingly, PPAR𝛼 regulation of mitochondrial
metabolism may be exploited for cancer treatment. Many
cancer types exhibit highly glycolytic metabolism, and
cancer cell’s mitochondria have a strong commitment toward
anabolism and cataplerosis. Since TCA intermediates are
used mainly in biosynthetic reactions, mitochondria of
cancer cells often have scarce OXPHOS and rely mainly
on glycolysis for ATP production. Activation of PPAR𝛼
induces pyruvate dehydrogenase kinase 4 (PDK4) [97],
which inhibits the pyruvate dehydrogenase complex, thus
preventing pyruvate from glycolysis to enter mitochondria
for acetyl-CoA synthesis and anaplerosis. The net result is
the blockage of TCA and fatty acid synthesis, which requires
acetyl-CoA, and the slowing-down of glycolytic rate [98].
Activation of PPAR𝛼 suppresses anaplerosis from glu-
tamine, by repressing the expression of glutaminase and
glutamate dehydrogenase, thus potentially counteracting c-
myc-dependent activation of glutaminolysis in tumor [97].
Therefore, the transrepression activity of PPAR𝛼 on
lipid biosynthesis and anaplerosis is just as relevant as
its transactivation activity on FAO genes. The transrepres-
sion activity of PPAR𝛼 indeed impacts on mitochondria
metabolism through SIRT1, by competing with ERR tran-
scriptional pathway [99]. Interestingly, Pawlak and colleagues
recently showed that the transrepression activity of PPAR𝛼
also regulates the inflammatory response in liver, preventing
transition from NAFLD to NASH and fibrosis, and occurs
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independently on PPAR𝛼 DNA binding activity and its lipid
handling properties [100].
A very recent report established a direct connection bet-
ween PPAR𝛼-driven FAO and hepatocyte proliferation.
CyclinD1, expressed in proliferating cells and a typical pro-
tooncogene, was found to inhibit PPAR𝛼 expression, thereby
reducing 𝛽-oxidation, both in normal hepatocytes and in
HCC cells lines. This link was confirmed also in liver after
partial hepatectomy, where induction of CyclinD1 timed with
a reduction of PPAR𝛼 and its target genes [101].
4.2. PPAR𝛽/𝛿. As summarized above, PPAR𝛽/𝛿 functions
significantly overlap with PPAR𝛼 in peripheral tissues, while
in the liver its functions are more closely related to PPAR𝛾
regulated processes.
In genetic mice model of NAFLD (ob/ob), adenoviral
overexpression of PPAR𝛽/𝛿 reduced the lipogenic program
activated by SREBP-1c, via downregulation of the SREBP-
1c activator insig-1, thus ameliorating hepatic steatosis [102].
Conversely, increased activation of SREBP-1c was found in
PPAR𝛽/𝛿−/− versus WT mice, fed either a control or ethanol
liquid diet [103], suggesting that PPAR𝛽/𝛿may play a role in
suppressing the lipogenic pathway trough SREBP-1c.
In another study, adenoviral-mediated overexpression of
PPAR𝛽/𝛿 in hepatocytes improved glucose utilization and
hepatic insulin sensitivity. After overnight fasting, PPAR𝛽/𝛿
overexpressing livers had higher triglyceride and glyco-
gen content than wild-type mice, while fatty acids and
cholesterol level were similar [38]. Moreover, adenoviral-
mediated overexpression in C57/BL6mice induced SREBP-1c
and PGC-1𝛽 expression. PPAR𝛽/𝛿 overexpression protected
mice liver from fatty acid overload by promoting (i) FA
conversion into nontoxicMUFA and (ii) FA storage into lipid
droplets as triglycerides (Figure 2). As a result, activation
of inflammatory pathways by FA overload was reduced in
PPAR𝛽/𝛿 overexpressing mice fed HFD although steatosis
was increased [38]. Treatment of db/db mice with the
high affinity PPAR𝛽/𝛿 ligand GW501516 resulted in marked
increase of genes involved in fatty acids synthesis and pentose
phosphate pathways, promoting FA synthesis in the liver (in
parallel with FA oxidation in muscle) [104].
These discrepancies are difficult to reconcile and might
be related to the different mice model used, although in
both genetic and dietary models PPAR𝛽/𝛿 has been shown
to either promote or inhibit liver lipogenesis. Moreover,
PPAR𝛽/𝛿 inhibits hepatic FGF21 expression [105], while
PPAR𝛼 is a potent activator of FGF21 [20]. Since FGF21 is
known to inhibit SREBP-1c and several other lipogenic genes
in the liver [106, 107], the potential cross-talk of different
PPAR isotypes on FGF21 may contribute to eliciting context-
dependent effects.
Despite these striking differences, activation of PPAR𝛽/𝛿
consistently resulted in a beneficial effect on liver damage.
Pharmacological activation of PPAR𝛽/𝛿 has been exp-
lored in several rodents and human studies. Administration
of PPAR𝛽/𝛿 agonists improved hepatic steatosis and reduced
insulin resistance and hepatic inflammation [71, 108–111].
Consistently, PPAR𝛽/𝛿−/− mice were prone to inflammation
derived liver damage.
In humans, PPAR𝛽/𝛿 agonists for NASH treatment are
currently under investigation in clinical trials. The first evi-
dence in men was obtained with GW501516, which proved to
be equal to the PPAR𝛼 agonist GW590735 in reducing plasma
triglycerides levels and superior to the PPAR𝛼 agonist in
reducing cholesterol LDL, apolipoprotein B, liver fat content,
and urinary isoprostane [112]. More recently, the PPAR𝛽/𝛿
agonist MBX-8025 was tested in 181 dyslipidemic patients in
combination with atorvastatin or alone. MBX-8025 proved
effective in reducing apolipoprotein B levels, non-HDL-
cholesterol, triglycerides, free fatty acids, and high-sensitive
C-reactive protein [113].
PPAR𝛽/𝛿-driven mitochondriogenesis has been impli-
cated in the differentiation of hepatic-like tissue from mouse
of ES cells [41]. At the early phase of differentiation, a transi-
tory upregulation of PPAR𝛼 was observed, which resulted in
induction of PGC-1𝛼 and mitochondriogenesis. Instead, the
late phase of differentiation required a robust and sustained
expression of PPAR𝛽/𝛿, which was timely associated with
albumin expression and acquisition of high mitochondrial
membrane potential. PPAR𝛽/𝛿 agonists L165041 promoted
differentiation into hepatic-like tissue that was abolished
by PPAR𝛽/𝛿 inhibitor GSK0660 [41]. Therefore, PPAR𝛽/𝛿
may promote terminal hepatocyte differentiation associated
with acquisition of mature mitochondria metabolism and
function.
Indeed, PPAR𝛽/𝛿−/− mice show a delay in liver regener-
ation after partial hepatectomy, associated with lack of Akt
activation, lack of induction of glycolytic and lipogenic genes,
and suppression of E2F transcription factors activation [114].
Interestingly, PPAR𝛽/𝛿 was associated with nonprolif-
erating hepatocytes in a gene signature analysis of nuclear
receptor in proliferating livers and HCC [115]. The authors
analyzed the expression of all 49 members of the nuclear
receptor superfamily in regenerating mouse liver and
PPAR𝛽/𝛿 (together with TR𝛼 and FXR𝛽) was found con-
sistently downregulated throughout the process. PPAR𝛽/𝛿
was found significantly reduced in a small series of HCC
with respect to the surrounding nontumoral tissue and the
PPAR𝛽/𝛿 agonist GW501516 suppressed CyclinD1 expression
and cell proliferation inHepa1-6 cells [115]. However, whether
PPAR𝛽/𝛿 agonists suppress HCC cells growth is still con-
troversial [116, 117]. Both PPAR𝛽/𝛿 and PPAR𝛾 have been
implicated in mediating beta-catenin-Tcf/lef signaling [118].
Recently, PPAR𝛽/𝛿 was identified as a target gene of
FHL2, a tumor suppressor gene also involved in hepatocel-
lular carcinoma [119, 120].
4.3. PPAR𝛾. The effectiveness of the insulin sensitizers TZD
in ameliorating the lipidemic profile, inflammation, and
steatosis in T2DMpatients is well established. Several clinical
trials have explored the potential of TZDs in the treatment of
NASH and have recently been reviewed [121, 122].
A recentmeta-analysis of RCTonTZDandNASH (3with
pioglitazone, 1 with rosiglitazone) confirmed the effectiveness
of TZD in improving steatosis, necroinflammation, and
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hepatocyte ballooning [123]. A significant improvement in
fibrosis was obtained only when the analysis was restricted to
the pioglitazone studies only. Rosiglitazone failed to improve
necroinflammation, ballooning, and fibrosis in the 1-year
FLIRT trial [124] and even when treatment was extended
for additionally 2 years [125]. Combinatory treatment of
rosiglitazone withmetformin or losartan did not improve the
histological endpoint versus rosiglitazone alone [126]. A very
recent report suggests that rosiglitazone administration may
exert opposite outcome on liver steatosis depending on liver
PPAR𝛾 expression levels: RGZ worsen steatosis in PPAR𝛾
overexpressing mice fed a HFD and protected mice with low
PPAR𝛾 expression level [121, 127].
PPAR𝛾 is indeed markedly overexpressed in the liver
of obese patients with NAFLD and NASH, and its expres-
sion positively correlates with plasma insulin, HOMA-IR,
and SREBP1-c mRNA levels and inversely correlates with
adiponectin [128]. High PPAR𝛾 levels, in particular of
PPAR𝛾2, promotes de novo lipogenesis and liver steatosis
and is associated with HFD feeding in mice [129–131].
However as recalled above, induction of PPAR𝛾 by TZD,
in particular pioglitazone, ameliorates steatosis and NASH.
This discrepancy may be interpreted in the light of the
double nature of PPAR𝛾 target genes, which comprises both
genes of de novo lipid synthesis and mitochondrial genes
promoting FAO [132]. Moreover, pioglitazone also binds and
activates PPAR𝛼with low potency [133], which could explain
its better performance than rosiglitazone in ameliorating
steatosis. Mechanistically, induction of PPAR𝛾 in steatotic
hepatocytes may serve as a protective mechanism to reduce
liver FFA levels by storing them as less toxic triglycerides
[134, 135]. Therefore, the prosteatotic action of PPAR𝛾 [136]
may not be entirely detrimental. However, excess triglyceride
accumulation eventually results in hepatocyte ballooning and
necroinflammation, promoting transition to NASH.
The role of PPAR𝛾 in hepatocellular carcinoma is still
debated. A large body of literature on PPAR𝛾 and cancer was
produced using TZD, which eventually were proved to have
several anticancer pleiotropic effects also independently of
PPAR𝛾 [137–140].
We and others have investigated the role of PPAR𝛾
on hepatocarcinogenesis in mice harboring a hepatocyte
specific deletion of PPAR𝛾 gene (PPAR𝛾ℎ𝑒𝑝−/− mice). Yu and
colleagues found increased DEN-induced HCC inmice lack-
ing one PPAR𝛾 allele, thus suggesting a tumor-suppression
function for PPAR𝛾 [141]. Moreover, RGZ reduced HCC
development in DEN-treated WT mice but not in PPAR𝛾+/−
mice [141]. Using a transgenic model of HBV-related HCC,
we found that RGZ or PGZ effectively reduced HCC onset
[142]. Strikingly, TZD treatment resulted more effective in
PPAR𝛾ℎ𝑒𝑝−/− mice than in WT mice [142], highlighting that
(i) TZD antitumor activity is independent of PPAR𝛾; (ii)
PPAR𝛾 expression reduced TZD activity; therefore in this
model PPAR𝛾 may support, rather than inhibiting, tumor
growth.
As the master regulator of adipogenic differentia-
tion, PPAR𝛾 has been described to promote differentia-
tion programs in a variety of tumor cell types [143, 144],
inducing cell-cycle arrest [145], apoptosis/anoikis [146–148],
and inhibiting EMT [149, 150], angiogenesis [151], andmetas-
tasis [152].
However, several lines of evidence also support the
notion that this nuclear receptor may support the growth in
several cancer types. Conflicting results have been reported
in breast cancer model. Recently, Avena et al. showed that
breast cancer growth was inhibited by PPAR𝛾 overexpression
epithelial cancer cells but promoted byPPAR𝛾overexpression
in cancer associated stroma [153]. The authors identify the
tumor promoting role of PPAR𝛾 in the metabolic symbiosis
between stoma and epithelial cancer cells, where cancer asso-
ciated fibroblasts provided intermediates for mitochondrial
metabolism to cancer cells [153].Moreover, increased de novo
lipogenesis, that is promoted by PPAR𝛾, is now recognized
as a metabolic hallmark of cancer cell [154], including
HCC [155–159] (Figure 2). Indeed, de novo lipogenesis is
activated downstream of the Akt/mTOR pathway, one of the
most common signaling pathways altered in cancer. Forced
activation of Akt/mTOR induces liver cancer [160, 161], a
process mediated at least in part by activation of FASN
[155, 156]. Consistently, inactivation of FASN was recently
shown to completely inhibit Akt-driven HCC in mice
[158]. Importantly, FASN is not oncogenic per se. However,
when the PI3K/Akt/mTOR pathway becomes hyperactive,
the induction of the de novo lipogenesis is a requisite for
supporting cancer cell growth. Importantly, PPAR𝛾 is a direct
transcriptional target of mTORC1 [162]. Moreover, in PTEN
null mice PPAR𝛾was found to directly induce the expression
of key glycolytic gene HK and oncogenic PKM2, inducing
hepatocyte steatosis, hypertrophy, and hyperplasia [163].
Therefore, PPAR𝛾 may inhibit or promote HCC devel-
opment depending on the metabolic context, the cell type
expressing it, the oncogenic signaling pathways involved, and
dietary or pharmacological treatment. It is however con-
ceptually very attractive to explore the therapeutic potential
interference with the cancer cell lipid handling capacity,
through modulation of mitochondrial FA, ketogenesis, and
lipogenesis, as an integrated anticancer approach.
5. PPARs and Circadian Regulation of
Mitochondria Metabolism
Many processes of our metabolism and physiology are
regulated by circadian clocks, endogenous time-tracking
systems that coordinate daily rhythms of rest, activity, feeding
behavior, energy utilization, and storage. Although circadian
rhythms are endogenous they respond to external stimuli,
which include light, temperature, and redox cycles [164].
Circadian regulation is coordinated by the suprachiasmatic
nucleus in the brain, but most peripheral organs contain
their own independent pacemakers [165]. At a cellular level
these oscillations are driven by transcriptional feedback loops
associated with changes in chromatin remodeling, mRNA
processing, protein turnover, and activity [166–169]. Main
factors that control circadian rhythmicity in the cells include
BMAL1 and CLOCK (“activators”) and CRYs and PERs
(“inhibitors”). Their effects are tissue-specific and in the liver
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they control approximately 10% of the transcriptome [170],
influencing metabolic pathways by modifying the expression
or activity of key enzymes and transporters involved in lipid,
glucose, and mitochondrial oxidative metabolism. Recip-
rocally, intracellular metabolites and transcriptional factors
modulate CLOCK activity in response to the energy status.
Circadian dysregulation of lipid metabolism, ROS pro-
duction, and cell-cycle control is linked to various patho-
logical conditions including metabolic syndrome, diabetes,
chronic liver diseases, and cancer [171–173].
5.1. Clock and Lipid Metabolism: Regulation of PPARs and
Mitochondrial Functions. The redox state of the cell also
seems to play an important part in the rhythmicity of
metabolism, especially in the mitochondria. NAD+ levels
oscillate and are under direct control of clock transcription
factors that upregulate the rate-limiting enzyme in NAD+
biosynthesis, NAMPT (nicotinamide phosphoribosyl trans-
ferase). In mitochondria NAD+ activates SIRT3, an impor-
tant regulator of intrinsic mitochondrial function including
FAO. In the cytoplasm NAD+ activates SIRT1 that operates
a small feedback regulating Clock and Bmal. Disruption
of circadian rhythms in mice leads to defects in mtFAO
and decreased OCR mainly through deregulation of NAD+
dependent SIRT3 activity [174, 175] (Figure 2).
Several genes involved in lipid metabolism (such as
SREBP, HMGCoAR, and FAS) are modulated by PPAR𝛼 and
display circadian fluctuations that are lost in PPAR𝛼-KOmice
[176, 177].
PPAR𝛼 is a direct transcriptional target of BMAL1 and
CLOCK [178–180] and in the rodent liver operates a feed-
back loop binding BMAL1 and REV-ERB𝛼 gene promoters.
BMAL1-KO and CLOCK-mutant mice display abolished
PPAR𝛼 oscillation and decreased expression in the liver,
whereas PPAR𝛼-KO mice display altered oscillation of PER3
and BMAL1 [181]. Moreover, administration of PPAR𝛼 ago-
nists fenofibrates upregulates the expression of Bmal1 in
mouse liver [180].
Fatty acids are known to be PPAR𝛼 activators, binding
directly to the transcriptional factor. Interestingly, hepatic
fatty acids are also produced in a circadian manner by acyl-
CoA thioesterases (ACOTs) and lipoprotein lipases (LPLs).
The expression of both enzyme families displays circadian
rhythmicity; it is regulated by PPAR𝛼 and can in fact
be induced by WY14643. Moreover, silencing members of
ACOTs lead to a downregulation of Cyp4a10 and Cyp4a14,
PPARa targets [182–186].
Another clock controlled gene, Nocturnin, binds to
PPAR𝛾 modulating its transcriptional activity [187], and
PPAR𝛾 systemic inactivation inmice leads to impaired rhyth-
micity of the canonical clock genes in liver and adipose tissues
[188]. PGC-1𝛼 is also rhythmically expressed in mouse liver
and muscle, upregulates circadian factors BMAL1, CLOCK,
and REV-ERB𝛼 [189], and modulates the length of circadian
oscillations by controlling Bmal1 transcription in a REV-
ERB-dependent manner. Mice lacking PGC-1𝛼 show abnor-
mal circadian rhythms and altered expression of metabolic
genes [189]. Interestingly, circadian regulation was lost also in
mice lacking PGC-1𝛽, but this resulted inmarkedly decreased
activity during the dark cycle, as opposed to the hyperactive
PGC-1𝛼 KOmice [190] (Figure 2).
The liver-specific deletion of PPAR𝛿 in mice showed that
it is involved in the temporal regulation of several lipogenic
genes, such as fatty acid synthase (FAS) and acetyl-CoA
carboxylase 1 and acetyl-CoA carboxylase 2 [40]. BMAL1 also
induces the expression of REV-ERB𝛼, a nuclear receptor that
downregulates BMAL1 itself, operating a negative feedback,
and upregulates the expression of a liver-specific microRNA:
miR-122 [191]. miR-122 is also involved in lipid metabolism
in mouse liver [192] and PPAR𝛿 was proven to be one of
its targets, suggesting that PPAR𝛿 plays a role in hepatic
circadian regulation [193].
The circadian regulation of mitochondrial metabolism is
still in its early days. Using a MS-based proteomic approach,
the expression of rate-limiting enzymes and metabolites in
mitochondria was quantitatively evaluated throughout the
day [194]. Many key mitochondrial enzymes involved in
carbohydrates and lipidmetabolismwere found to peak in the
earlymorning period and to be regulated by PER2/3 proteins.
Mitochondrial respiration displayed an oscillatory behavior,
peaking several times of the day. In mice KO for Per2/3, as
well as in those fed aHFD, period protein oscillation was lost,
together with OXPHOS oscillation [194].
5.2. Circadian Disturbances in Liver Disease. It is now clear
that circadian rhythms are fundamental in liver physiology
and their disruption is observed in many hepatic pathologic
conditions, such as NASH, NAFLD, ALD, and HCC [110, 172,
195–198].
In a mouse model of NASH it was found that HFD
induces the susceptibility to develop NASH through desyn-
chronized Clock gene expression and altered cellular redox
status, accompanied by reduced sirtuin abundance [197].
HFD in mice is sufficient to induce the loss of circadian
fluctuations of insulin secretion [199]. Conversely, BMAL1
whole body-KOmice and Clock-mutantmice display hepatic
steatosis, obesity, hypoinsulinemia, and increased glucose
intolerance [200].
The molecular alterations found in the liver of HFD-fed
mice include loss of oscillation or phase advance of rhyth-
micity of many genes involved in lipid and mitochondrial
metabolism (such asNAMPT, acetyl-coenzymeA synthetase,
and ornithine decarboxylase 1) and gain of oscillation of other
genes such as PPAR𝛾 and its targets [201].This transcriptional
reprogramming relies on changes in the oscillation and chro-
matin recruitment of PPAR𝛾 that also induces the oscillation
of Cidec (cell death activator CIDE-3) [201], a protein that
is substantially elevated in the livers of the obese ob/ob
mice [202]. Administration of GW9662, a specific PPAR𝛾
antagonist, into HFD-fed animals produced a decrease in
PPAR𝛾-induced Cidec expression [201]. The expression of
another known PPAR𝛾 target, pyruvate carboxylase (Pcx), an
important regulator of hepatic gluconeogenesis, was signifi-
cantly elevated and rhythmic in livers of HFD-fedmice [201].
InNocturnin-KOmice fedwithHFD, liver PPAR𝛾 oscillation
was abolished, accompanied by a reduced expression ofmany
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genes related to lipid metabolism and resistance to hepatic
steatosis [203].
Accumulating evidence supports the importance of the
disruption of circadian rhythms in various types in cancer.
Specifically, in HCC patients, low expression of clock genes
was observed in the cancerous tissue, but not in the non-
cancerous liver tissue, and correlated with tumor size and
tumor grade [204]. A number of mechanisms may explain
the circadian control on HCC. For example, it was found
that DEN exposure in mice is associated with circadian
disturbance, suggesting that liver clocks are involved in the
carcinogenesis [196]. Mutations and polymorphisms of the
clock proteins are being screened to assess their association
with HCC. Interestingly, a functional polymorphism of PER3
was recently associated with a lower risk of death in HCC
patients treated with TACE [205].
6. Perspectives and Conclusions
It is now clear that expression or activation of nuclear rec-
eptors, including PPARs, is not sufficient to predict their
biological output. The net effect of a nuclear receptor acti-
vation in a given cell actually depends on the context of
coactivators, corepressors, dimerization events, availability
of endogenous/synthetic ligands, posttranslational modifica-
tions, competition, and interactions with other NRs. This led
to the development of partial agonist selective PPARmodula-
tors (SPPARMs), a second generation of PPAR agonists able
to selectively activate a subset of target genes downstream a
specific PPAR isotype.
K-877 is a SPPAR𝛼M currently being tested in dyslipi-
demic patients that exhibits higher lipid lowering activity
than fibrates and has a favorable risk profile [206, 207].
INT-131, SPPAR𝛾M, has potent glucose lowering effects not
associated with TZD side-effects [208].
A different approach to PPARmodulation is to simultane-
ously activate, with different potency, more than one isotype:
dual PPAR agonist or pan-agonists are currently under
investigation. The dual PPAR𝛼/𝛿 agonist GFT-505 is proving
effective in reducing plasma triglyceride levels, improving
insulin sensitivity, and increasing HDL-cholesterol in obese
patients [209, 210] and showed promising results in mice
model of NASH [211]. Very recently a phase 2 multicenter
randomized controlled trial, enrolling 274 subjects with
histologically proven NASH, showed that GFT505 produces
a dose-dependent improvement in histology of patients with
NASH [212].
As we gain knowledge of the metabolic circadian regu-
lation and of its disruption in disease, an entire new area
of intervention begins to emerge. Modulation of amplitude
and phase of PPARs circadian regulation could be exploited
to drive complex metabolic remodeling of mitochondrial
metabolism inNASH and cancermodels. Finally, the integra-
tion of the above-mentioned approaches with the metabolic
and genetic profiling of cancers holds the promise for new
therapeutic approaches that can selectively target the fuel
requirements of HCC.
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TR𝛼: Thyroid hormone receptor
alpha (TR-alpha)
UCP-1, UCP-2, and UCP-3: Mitochondrial uncoupling
protein 3
4-HNE: 4-hydroxynonenal.
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